Repurposing CD8 <sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic? — Shashi Gujar (2020) | RDL Network
Repurposing CD8 <sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
Article 2020 en
Authors
SG
Shashi Gujar
JP
Jonathan Pol
YK
Youra Kim
Abstract
1 min read
The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.
Uwe Riedmann, Alena Chalupka, Lukáš Richter, Martin Sprenger, Wolfgang Rauch, Hannes Schenk, Robert Krause, Peter Willeit, Herbert Oberacher, Tracy Beth Høeg, John P A Ioannidis, Stefan Pilz
Uwe Riedmann, Alena Chalupka, Lukáš Richter, Martin Sprenger, Wolfgang Rauch, Hannes Schenk, Robert Krause, Peter Willeit, Herbert Oberacher, Tracy Beth Høeg, John P A Ioannidis, Stefan Pilz
Anna H.E. Roukens, Cilia R. Pothast, Marion König, Wesley Huisman, Tim J. Dalebout, Tamar Tak, Shohreh Azimi, Yvonne C. M. Kruize, Renate S. Hagedoorn, Mihaela Zlei, Frank J. T. Staal, Fenna De Bie, Jacques J. M. van Dongen, M. Sesmu Arbous, Jaimie L. H. Zhang, Maaike Verheij, Corine Prins, Anne M. van der Does, Pieter S. Hiemstra, Jutte J.C. de Vries, Jacqueline J. Janse, Meta Roestenberg, ,
Discussion(0)
No comments yet. Be the first to comment.